Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Microbix Biosystems Inc. (T:MBX)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Company Contact
Address: 265 Watline Avenue
MISSISSAUGA ON L4Z 1P3
Tel: N/A
Website: https://microbix.com
IR: See website
Key People
Cameron L. Groome
President, Chief Executive Officer, Director
James S. Currie
Chief Financial Officer
Philip J. Casselli
Senior Vice President - Sales and Business Development
Mark Luscher
Senior Vice President - Scientific Affairs
   
Business Overview
Microbix Biosystems Inc. is a Canada-based company, which develops and commercializes biological and technology solutions. The Company manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The Company operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The Company's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
Financial Overview
For the six months ended 31 March 2022, Microbix Biosystems Inc revenues increased 30% to C$9.7M. Net income increased 72% to C$1.6M. Revenues reflect Kinlytic and Lumisort segment increase from C$2K to C$4K, North America segment increase of 86% to C$7.5M, Other foreign segment increase from C$4K to C$10K. Basic Earnings per Share excluding Extraordinary Items remained flat at C$0.01.
Employees: 69 as of Sep 30, 2015
Reporting Currency: Canadian Dollars
Enterprise value: $58.16M as of Mar 31, 2022
Annual revenue (TTM): $20.82M as of Mar 31, 2022
EBITDA (TTM): $6.34M as of Mar 31, 2022
Net annual income (TTM): $3.91M as of Mar 31, 2022
Free cash flow (TTM): $0.66M as of Mar 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 137,291,374 as of May 13, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization